Abstract: Positron emission tomography (PET) has become the leading technology in the field of nuclear medicine. Currently, PET is widely used in tumor research, with high sensitivity, good resolution and so on. The construction of the ⁶⁸Ge/ ⁶⁸Ga generator has increased the application of ⁶⁸Ga radiopharmaceuticals. The ⁶⁸Ga radiopharmaceuticals are mainly applied on the imaging of oncological diseases, such as the targeting imaging of somatostatin receptor, human epidermal growth factor receptor, folate and so on. The potential for imaging of pulmonary and myocardial perfusion and ventilation as well as targeting imaging of inflammation, infection, have also been considered and fundamental exploration is ongoing. The application progress of ⁶⁸Ga radiopharmaceuticals was reviewed, including production, receptors and derivatives, imaging of pre-clinical developments on diagnosis.